含吉西他滨的联合化疗方案治疗难治性非霍奇金淋巴瘤疗效

Efficacy Analysis of GEMOX Regimen for Treatment of Refractory Non-Hodgkin's Lymphoma

目的:探讨含吉西他滨联合化疗方案治疗难治性非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)的临床效果。方法:按照化疗方案不同将82例复发或难治性NHL患者分为2组:吉西他滨+奥沙利铂组(Gem+Oxa)(42例)和长春瑞滨+奥沙利铂组(Vin+Oxa)(40例),比较2组患者疗程结束后临床疗效、毒副反应及无进展生存率。结果:Gem+Oxa组患者总有效率略高于Vin+Oxa组,但无统计学意义(P>0.05);2组B细胞淋巴瘤患者临床总有效率均显著高于T细胞淋巴瘤,Ⅰ-Ⅱ期临床总有效率均显著低于Ⅲ-Ⅳ期,差异具有统计学意义(P<0.05);Gem+Oxa组患者血小板下降、恶心呕吐及周围神经症状发生率及严重程度均显著低于Vin+Oxa组(P<0.05);根据生存时间曲线,两组间比较差异无统计学意义(P>0.05)。结论:含吉西他滨联合化疗方案治疗NHL临床疗效显著,可明显延长患者无进展生存期,尤其对B细胞淋巴瘤患者以及Ⅲ-Ⅳ期NHL患者效果更佳,可作为治疗难治性NHL的优选方案。

Objective： To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin＇ s lymphoma. Methods： Eighty-two cases of non-Hodgkin＇ s lymphoma were divided into 2 groups： gemcitabine ＋oxaliplation（Gem ＋ Oxa） group（42 cases） and vinorelbine ＋ oxaliplatin（Vin ＋ Oxa） group（40 cases） according to chemotherapy regimens. The clinical efficacy,side effects,progression-free survival situation in 2 groups were compared.Results： There was no significant difference on the clinical effects of 2 groups（P〈0. 05）; The therapeutic efficacy for B cell lymphoma was higher than that for T cell lymphoma（P〈0. 05）; The therapeutic effects for Ⅰ-Ⅱ stages was lower than that for Ⅲ-Ⅳ stages（P〈0. 05）; The incidences of platelet decline,nausea and vomit,peripheral nerve symptoms in Gem ＋ Oxa group were lower than those in Vin ＋ Oxa group（P〈0. 05）; There was no significant difference in the median progression free survival（ P〈0. 05）. Conclusion： The efficacy of GEMOX regimen for refractory non-Hodgkin＇ s lymphoma has been confirmed to be good,it has distinct clinical curative effect,it can prolong the progression-free survival time in patients with B cell lymphoma,specially for Ⅲ-Ⅳ stages. It can be used as the preferred method for the treatment of patients with refractory NHL.